Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Single-Arm, Phase 1/2 Study Evaluating the Safety and Efficacy of Ponatinib for the Treatment of Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors in Pediatric Participants

NCT03934372 is registered in ClinicalTrials.gov with Incyte Biosciences International Sàrl as lead sponsor.

NCT NCT03934372
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03934372 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Single-Arm, Phase 1/2 Study Evaluating the Safety and Efficacy of Ponatinib for the Treatment of Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors in Pediatric Participants
Lead sponsor
Incyte Biosciences International Sàrl
Phase
Phase 1/2
Overall status
Recruiting
Start date
January 29, 2020
Completion date
February 1, 2028
Enrollment
70 (estimated)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

accelerated phase chronic myeloid leukemia, acute lymphoblastic leukemia, acute lymphocytic leukemia, acute myeloid leukemia, blast phase chronic myeloid leukemia, chronic phase chronic myeloid leukemia, leukemia, lymphoma, solid tumors